Zoetis v. Farmabase: Azalide Antibiotic Patent Invalidity Appeal Dismissed
Farmabase Saúde Animal Ltda challenged the validity of two Zoetis azalide macrolide antibiotic patents before the Court of Justice of São Paulo. The court rejected the motion for clarification and dismissed the appeal, leaving Zoetis’s patent rights intact as of January 2025.
Filing to Appeal Dismissed in 0 days
Case closed 10 January 2025 — Court of Justice of São Paulo
Appeal dismissed: what the São Paulo ruling means for both parties
Procedural dismissal — no merits reversal granted
The court rejected Farmabase’s motion for clarification, finding no cognisable defects in the prior ruling, and dismissed the appeal. A dismissal at this stage means the appellate court declined to disturb the underlying decision. No substantive ruling on the invalidity of the patents was issued at this appellate level — the challenge was extinguished on procedural grounds.
Appeal ended without merits rulingZoetis’s azalide patents survive the invalidity challenge
With the appeal dismissed, BRPI9810519B1 and BRPI9915480B1 remain in force in Brazil. Zoetis retains the right to enforce both patents covering 13-membered azalide compositions and 4”-substituted 9a-aza-homoerythromycin derivatives. The outcome strengthens Zoetis’s commercial position in the Brazilian veterinary and pharmaceutical antibiotic market absent any further challenge.
Patents remain enforceable in BrazilFarmabase’s invalidity route is closed at this appellate level
Farmabase’s motion for clarification — the procedural vehicle for the appeal — was rejected in full. The challenger would need to identify a distinct legal basis to mount any further challenge, such as an administrative nullity action before Brazil’s INPI or a separate judicial route. The public record does not indicate any parallel proceedings are underway.
Invalidity challenge exhausted hereAzalide antibiotic IP in Brazil: higher bar for generic entrants
The dismissal reinforces the durability of originator macrolide/azalide patents in Brazilian courts when challenged through post-grant invalidity actions. Animal health and pharmaceutical companies seeking to commercialise competing azalide formulations in Brazil should treat this outcome as a signal that Zoetis’s patent estate in this class is well-defended and that freedom-to-operate analysis remains essential before market entry.
Originator patent position reinforcedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Zoetis Services Llc. | Company | Search in Eureka ↗ |
| Defendant | Farmabase Saúde Animal Ltda | Company | Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Justice of Sao PauloSearch in Eureka ↗ |
Official order — verbatim text
The court’s formulation — ‘the alleged defects have not been verified, I REJECT the motion for clarification’ — is characteristic of Brazilian appellate procedure where embargos de declaração (clarification motions) are dismissed when no omission, contradiction, or obscurity is found. This language confirms no substantive re-examination of the invalidity merits occurred; the prior ruling stands by operation of procedural law rather than fresh analysis.
BRPI9810519B1 & BRPI9915480B1 — Azalide Macrolide Antibiotic Patents
BRPI9810519B1 covers 13-membered azalide compounds — a subclass of macrolide antibiotics structurally related to azithromycin — including their pharmaceutical compositions, preparation methods, and therapeutic uses. BRPI9915480B1 covers derivatives of 4”-substituted 9-deoxo-9a-aza-9a-homoerythromycin A and related pharmaceutical compositions. Both patents are Brazilian national phase grants originating from late-1990s priority filings, placing them in the era of intensive macrolide antibiotic development.
Azalide macrolides are commercially significant in both human and veterinary medicine as broad-spectrum antibiotics. Zoetis, as a global animal health company, holds these patents strategically to protect veterinary antibiotic formulations in Brazil — a large agricultural and livestock market. A competitor entering the Brazilian market with any azalide-class veterinary antibiotic product must account for both patents. The survival of these grants after Farmabase’s challenge reinforces their commercial blocking power.
Should you run an FTO against BRPI9810519B1 and BRPI9915480B1?
Any company developing, importing, or distributing azalide macrolide antibiotic products — particularly veterinary pharmaceuticals — in Brazil should treat both patents as active blocking rights. The failed invalidity challenge by Farmabase confirms both patents have withstood judicial scrutiny. Animal health manufacturers, generic pharmaceutical developers, and API suppliers operating in Brazil face direct infringement exposure if their products fall within the claim scope of either patent.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of BRPI9810519B1 and BRPI9915480B1 against your candidate compound or formulation. It cross-references Brazilian patent grant data, INPI prosecution history, and comparable macrolide patent families in other jurisdictions to identify design-around opportunities and assess whether your product requires a clearance opinion before Brazilian market entry.
Run a freedom-to-operate analysis on BRPI9810519B1 to assess your product’s exposure
Run FTO in Eureka →Similar Azalide & Macrolide Patent Invalidity Cases in Brazilian Courts
Related invalidity and cancellation disputes involving macrolide antibiotic patents before Brazilian state and federal courts, including São Paulo Court of Justice proceedings.
What this case signals for the Brazilian animal health IP landscape
Farmabase’s failed challenge illustrates the procedural and substantive risks of contesting well-established originator antibiotic patents in Brazilian courts.
Brazilian courts show reluctance to disturb established pharma patent grants
The rejection of the clarification motion without finding any defects suggests the lower court’s original ruling was procedurally sound. Companies planning invalidity actions against Brazilian pharmaceutical patents should ensure their grounds are substantive and well-documented before filing — procedural challenges are unlikely to succeed at appellate level.
Azalide/macrolide FTO in Brazil requires active monitoring of Zoetis’s estate
With both BRPI9810519B1 and BRPI9915480B1 confirmed as surviving this challenge, any company developing or importing competing azalide antibiotic products for the Brazilian market faces enforceable blocking patents. A current FTO analysis against Zoetis’s Brazilian portfolio is strongly advisable before launch or scale-up decisions.
Zoetis v Farmabase — key questions answered
The Court of Justice of São Paulo dismissed Farmabase’s appeal on 10 January 2025, rejecting the motion for clarification and finding no defects in the prior ruling. Zoetis’s two azalide antibiotic patents, BRPI9810519B1 and BRPI9915480B1, remain valid and enforceable in Brazil.
Farmabase challenged BRPI9810519B1, covering 13-membered azalide compounds and their pharmaceutical compositions, and BRPI9915480B1, covering derivatives of 4”-substituted 9-deoxo-9a-aza-9a-homoerythromycin A. Both are Brazilian grants in the macrolide/azalide antibiotic class held by Zoetis Services LLC.
In Brazilian civil procedure, embargos de declaração (clarification motions) are used to correct omissions, contradictions, or obscurities in a court’s decision. When rejected, it means the appellate court found no such defects — the prior ruling is confirmed procedurally. No new merits analysis is conducted and the underlying decision stands unchanged.
The public record does not indicate parallel proceedings. A potential avenue would be an administrative nullity action before Brazil’s INPI, which can be filed independently of judicial proceedings. However, after a failed judicial challenge, the evidentiary threshold for a successful INPI action is practically higher, particularly if the same prior art grounds were already argued.
Yes. Zoetis is a global animal health company and azalide macrolides have established veterinary applications including treatment of respiratory and soft tissue infections in livestock. Both patents cover compositions and pharmaceutical formulations, meaning veterinary product developers and generic manufacturers in Brazil should conduct FTO analysis against these grants before commercialising competing azalide-class products.
PatSnap Eureka searches patents and litigation data to answer instantly.